Diabetes mellitus (DM) is a chronic disorder and has affected a large number of people worldwide. Insufficient insulin production causes an increase in blood glucose level that results in DM. To lower the blood glucose level, various drugs are employed that block the activity of the α-glucosidase enzyme, which is considered responsible for the breakdown of polysaccharides into monosaccharides leading to an increase in the intestinal blood glucose level. We have synthesized novel 2-(3-(benzoyl/4-bromobenzoyl)-4-hydroxy-1,1-dioxido-2H-benzo[e][1,2]thiazin-2-yl)-N-arylacetamides and have screened them for their in silico and in vitro α-glucosidase inhibition activity. The derivatives 11c, 12a, 12d, 12e, and 12g emerged as potent inhibitors of the α-glucosidase enzyme. These compounds exhibited good docking scores and excellent binding interactions with the selected residues (Asp203, Asp542, Asp327, His600, Arg526) during in silico screening. Similarly, these compounds also showed good in vitro α-glucosidase inhibitions with IC50 values of 30.65, 18.25, 20.76, 35.14, and 24.24 μM, respectively, which were better than the standard drug, acarbose (IC50 = 58.8 μM). Furthermore, a good agreement was observed between in silico and in vitro modes of study.
糖尿病(DM)是一种慢性疾病,已经影响了全球大量人口。胰岛素产量不足导致血糖水平升高,从而引发糖尿病。为了降低血糖水平,使用了各种药物来阻断α-葡萄糖苷酶的活性,该酶被认为是将多糖分解为单糖,导致肠道血糖水平升高的原因。我们合成了新型的2-(3-(苯甲酰/对溴苯甲酰)-4-羟基-1,1-二氧化-2H-苯并[e][1,2]噻嗪-2-基)-N-芳基乙酰胺,并对它们进行了体外和体内α-葡萄糖苷酶抑制活性的筛选。衍生物11c、12a、12d、12e和12g显示出对α-葡萄糖苷酶的强效抑制作用。这些化合物在体外筛选过程中表现出良好的对接得分,并与所选残基(Asp203、Asp542、Asp327、His600、Arg526)展现出优秀的结合相互作用。同样,这些化合物在体内也表现出良好的α-葡萄糖苷酶抑制作用,其IC50值分别为30.65、18.25、20.76、35.14和24.24 μM,优于标准药物阿卡波糖(IC50 = 58.8 μM)。此外,在体内和体外研究模式之间观察到了良好的一致性。